Hybrid Molecules from Xanomeline and Tacrine: Enhanced Tacrine Actions on Cholinesterases and Muscarinic M1 Receptors

被引:48
|
作者
Fang, Lei [2 ,3 ]
Jumpertz, Sabine [1 ]
Zhang, Yihua [2 ]
Appenroth, Dorothea [4 ]
Fleck, Christian [4 ]
Mohr, Klaus [1 ]
Traenkle, Christian [1 ]
Decker, Michael [3 ]
机构
[1] Univ Bonn, Inst Pharmazeut, D-53121 Bonn, Germany
[2] China Pharmaceut Univ, Ctr Drug Discovery, Nanjing 210009, Peoples R China
[3] Univ Jena, Inst Pharm, Lehrstuhl Pharmazeut Med Chem, D-07743 Jena, Germany
[4] Univ Jena, Inst Pharmakol & Toxikol, D-07740 Jena, Germany
关键词
HIGHLY POTENT; ACETYLCHOLINE-RECEPTORS; ALLOSTERIC INTERACTIONS; ALZHEIMERS-DISEASE; BINDING; LIGANDS; AGONISTS; DESIGN; SITE; MODULATORS;
D O I
10.1021/jm901616h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A set of amide- and amine-linked hybrid molecules comprising moieties of the orthosteric M-1 muscarinic receptor agonist xanomeline and the cholinesterase inhibitor and allosteric receptor modulator tacrine were prepared with varying spacer length of 10-17 atoms. The hybrids inhibited acetylcholinesterase with similar or higher potency compared to tacrine. M, receptor binding affinity was similar or higher relative to xanomeline and far higher relative to tacrine. Affinities hardly changed when the receptors' orthosteric site was Occupied by all inverse agonist ligand. When Occupied by the orthosteric activator acetylcholine, affinity for the hybrids declined to unmeasureably low levels. Hybrids did not activate M-1 receptors. In vivo studies assaying cognition impairment in rats induced by scopolamine revealed pronounced enhancement of scopolamine action. Taken together, instead of dualsteric (simultaneous allosteric/orthosteric) binding, the hybrids seem to prefer purely allosteric binding at the inactive M-1 receptor.
引用
收藏
页码:2094 / 2103
页数:10
相关论文
共 50 条
  • [31] Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor
    Christopoulos, A
    Parsons, AM
    El-Fakahany, EE
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 289 (03): : 1220 - 1228
  • [32] Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity
    Simon, T
    Becquemont, L
    Mary-Krause, M
    de Waziers, I
    Beaune, P
    Funck-Brentano, C
    Jaillon, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (04) : 432 - 437
  • [33] Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor
    Jakubík, J
    Tucek, S
    El-Fakahany, EE
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (03): : 1033 - 1041
  • [34] MUSCARINIC M1 RECEPTORS: INVOLVEMENT IN THE PATHOPHYSIOLOGY AND TREATMENT OF SCHIZOPHRENIA
    Dean, Brian
    Hopper, Shaun
    Scarr, Elizabeth
    [J]. SCHIZOPHRENIA BULLETIN, 2018, 44 : S70 - S71
  • [35] DISINHIBITION IN THE RAT SEPTUM MEDIATED BY M1 MUSCARINIC RECEPTORS
    HASUO, H
    GALLAGHER, JP
    SHINNICKGALLAGHER, P
    [J]. BRAIN RESEARCH, 1988, 438 (1-2) : 323 - 327
  • [36] IS THE EFFECT OF SOMATOSTATIN ON MUSCARINIC RECEPTORS SELECTIVE TO M1 TYPE
    MIYOSHI, R
    KITO, S
    MIZUNO, K
    MATSUBAYASHI, H
    [J]. BRAIN RESEARCH, 1986, 377 (02) : 348 - 350
  • [37] Recombinant expression of a selective blocker of M1 muscarinic receptors
    Näsman, J
    Jolkkonen, M
    Ammoun, S
    Karlsson, E
    Åkerman, KEO
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 271 (02) : 435 - 439
  • [38] M1 muscarinic acetylcholine receptors activate MAPK in brain
    Berkeley, JL
    Hamilton, SE
    Nathanson, NM
    Wess, J
    Levey, AI
    [J]. LIFE SCIENCES, 2001, 68 (22-23) : 2624 - 2624
  • [39] Muscarinic M1 receptors - A candidate gene for hypertension in the SHR
    Klett, CPR
    Bonner, T
    Printz, MP
    [J]. HYPERTENSION, 1997, 29 (03) : 196 - 196
  • [40] INTERACTION OF NEW ACETYLCHOLINESTERASE INHIBITORS WITH M1 MUSCARINIC RECEPTORS
    Sepsova, V
    Soukup, O.
    Marek, J.
    Karasova, Zdarova J.
    Kuca, K.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 267 - 267